Background {#Sec1}
==========

There is encouraging progress towards an AIDS-free generation by 2030 on a global scale. However, this progress is challenged by persistent poor outcomes among young people in sub-Saharan Africa (SSA). SSA accounts for 85% of the adolescents and young people living with HIV (AYPLHIV) worldwide. Almost one third of new HIV infections occur among individuals aged 15--25 years, mostly in females \[[@CR1], [@CR2]\]. AYPLHIV is the only population group for whom HIV-related mortality continues to increase and they are more likely to drop out of HIV care, and have overall worse health outcomes than all other age groups, especially in rural areas \[[@CR3]--[@CR7]\]. AYPLHIV face particular challenges in accessing and adhering to ART. The distinct rapid physical, psychological and emotional changes that occur during adolescence impact on how AYPLHIV perceive their health, make decisions, handle risks and interact with health and related services \[[@CR8]\]. Thus, barriers in the adolescent HIV care cascade are multifactorial \[[@CR9]--[@CR13]\]. Multicomponent packages of differentiated service delivery (DSD) are a promising approach to address these multiple barriers \[[@CR14], [@CR15]\]. Unlike service delivery models that apply standardized care for all people living with HIV, the idea of DSD models is to consider the specific needs of a group of people, while facilitating service scale-up by reducing the burden on health systems and increasing efficiency \[[@CR16], [@CR17]\]. In 2018, Paediatric-Adolescent Treatment Africa, in collaboration with other key stakeholders, undertook a situational analysis of DSD for AYPLHIV in South Africa \[[@CR18]\]. They report a lack of published literature documenting adolescent-specific DSD models in the Southern African region. Moreover, the analysis shows that most adolescents are not accessing DSD models even where they exist, an indicator that the existing DSD models are not tailored according to adolescent-specific preferences.

Many countries in SSA are expanding their peer-educator (PE) program and the World Health Organization (WHO) and International AIDS Society highly recommend engagement of peers in service delivery \[[@CR19], [@CR20]\]. The question arises to which extent PEs can be involved in coordinating DSD models and ART services for their peers. Some evidence exists, including a systematic review showing that PE involvement leads to improved engagement in care, psychosocial well-being and HIV knowledge, however, PE involvement is usually limited to support group interventions in urban settings with an unclear effect on biological outcomes \[[@CR21]--[@CR23]\]. One recent cluster-randomized clinical trial from rural Zimbabwe demonstrated a positive impact of peer-led services on psychosocial as well as virological outcomes for AYPLHIV \[[@CR24], [@CR25]\].

Lesotho has the second-highest HIV prevalence in the world with and adult prevalence of 25.6% and one of the highest HIV incidences among adolescent girls and young women \[[@CR1], [@CR26]\]. According to the recent household-based national survey (LePHIA) overall viral suppression in AYPLHIV is 50.9% among female and 46.1% among male \[[@CR27]\]. In close collaboration with different local stakeholders, we designed a DSD model specifically for AYPLHIV, called the PEBRA model, built upon existing support structures in Lesotho and delivered by a dedicated tablet application. In the PEBRA model, PEs first assess the ART service preferences of their peers, and then differentiate the services according to these preferences in a feasible manner.

Methods/design {#Sec2}
==============

Setting {#Sec3}
-------

The PEBRA trial will be conducted in northern Lesotho, in the districts of Leribe, Butha-Buthe and Mokhotlong. All districts are characterized by mostly rural settings, poor transport infrastructure and hard-to-reach villages with a combined estimated population of ca. 550′000. Butha-Buthe district comprises 12 public/missionary health facilities, Leribe district 26, and Mokhotlong district 10 that offer ART services. The HIV prevalence among individuals 15--59 years old ranges from 17.8% in Butha-Buthe, to 23.7% in Leribe and 26.1% in Mokhotlong \[[@CR27]\].

Design {#Sec4}
------

PEBRA trial is a cluster randomized, open-label, superiority trial in rural Lesotho. The clusters (health facilities) are randomized into two groups (intervention and control) in a 1:1 allocation stratified by district. Cluster randomization was applied to eliminate the risk of cross-contamination between the study arms.

Eligibility and randomization {#Sec5}
-----------------------------

Eligible clusters are public or missionary nurse-led health facilities (not hospitals) that offer ART services, serve a rural population, are situated in an area with stable cell phone signal and have a PE who passes the study-specific training assessment. Randomization is stratified by district due to differences in viral suppression rates across the districts. To obtain consent and to maximize transparency and ownership of the health facilities, randomization events involving all health facilities and the District Health Management Team were conducted in each district. At these events, health facility representatives drew opaque, sealed, equally sized envelopes containing the group allocation from a Mokorotlo (traditional Lesotho hat) and disclosure took place only once all facilities had drawn their envelope. To further ensure allocation concealment and to minimize potential selection bias, the sequence of drawing was randomly selected in advance by an independent person drawing from a second pile of opaque, sealed envelopes containing the names of the facility.

The PEs actively screen all young people at their facility for inclusion. Eligible individuals are attending care at a participating facility, take ART, 15--24 years old, and provide written informed consent.

Control clusters {#Sec6}
----------------

Participants in the control clusters receive the standard of care offered in Lesotho at nurse-led rural health facilities. The ART visits and refills are clinic-based and coordinated by the nurse. Some of the clinics have functioning clinic or community support clubs as well as SMS notifications to inform when VL results are available.

Intervention clusters {#Sec7}
---------------------

The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model, the ART services are coordinated by the PE as much as feasible and depending on the participants' preferences regarding medication pick-up, SMS notifications and support options. Details are outlined in Fig. [1](#Fig1){ref-type="fig"}. First, the PE explains all options to the participant who then chooses according to his/her preferences. Thereafter, the PE systematically assesses the feasibility of the option chosen as not all options are available to everyone all the time, e.g. no nearby Village Health Worker (VHW) available who could dispense ART, or no community youth club established in the participants' community, or home-delivery by the PE not being feasible. Finally, the compromise between preference and feasibility is delivered. The preferences are assessed at enrolment and thereafter follow a strict schedule: every month for participants with unsuppressed VL (\> 1000 copies/mL) and every 3 months for participants with suppressed VL. The PE delivers the PEBRA model using a tablet-based application, called PEBRApp (Fig. [2](#Fig2){ref-type="fig"}). The PEBRApp helps the PE to assess the preferences, to deliver them in a feasible manner, to keep track of the ART refill and next assessment dates, and to ensure regular contact between the PE and the participant. The PEBRApp is protected by a password and does not entail confidential patient information, i.e. names. The chosen SMS notifications are sent automatically through an external platform, and always include a call-back option to the PE's number. Fig. 1PEBRA intervention versus PEBRA control. ***Abbreviations:*** VHW (Village Health Worker), PE (Peer-Educator), CAC (Community Adherence Club), TB (Treatment Buddy), ART (antiretroviral therapy), VL (viral load), FP (Family Planning), VMMC (Voluntary Medical Male Circumcision), GBV (Gender-Based Violence), WORTH (Sentebale Social Asset Building Model). "Pitso" = Village gatheringFig. 2PEBRApp

The PEBRA model and PEBRApp were designed in collaboration with peer-educators, AYPLHIV, youth advocates, clinical staff and application developers during several workshops supported and coordinated by two local non-profit organizations (SolidarMed & Sentebale) as well as the Ministry of Health of Lesotho. The model incorporates the existing support structures at the health facilities. Sentebale is running a long-standing PE program in collaboration with the Ministry of Health. The study PEs are recruited from this existing PE program. They are trained young people living in a community of their respective health facility catchment area. All PEs involved in PEBRA trial receive an additional training on the PEBRApp and use of the tablet, referral and documentation system, obtaining informed consent and other study-specific procedures. Besides their usual close supervision by the health facility staff and Sentebale they are supervised by the study staff with regular onsite monitoring visits.

Outcomes {#Sec8}
--------

The primary endpoint is viral suppression at 12 months, defined as the proportion of participants in care with a documented VL \< 20 copies/mL 12 months (range: 9--15 months) after enrolment out of all participants enrolled, including participants who transferred out to any other health facility with documented proof of a VL laboratory report in the endpoint window. The secondary endpoints are defined in Table [1](#Tab1){ref-type="table"}. Furthermore, qualitative research to explore the acceptability of the PEBRA model and a cost-effectiveness analysis to estimate the impact of PEBRA model on health outcomes and costs will be conducted. Table 1Secondary endpoints of PEBRA trialSecondary endpoints***Definition**Time point following enrolment**Remarks***Engagement in careProportion of all participants engaged in care6 months (range 5--8) and 12 months (range 9--15)*Definition of "in care": at least one ART visit in the defined window*I. *Including participants who transferred out to any other health facility with known outcome (documented proof of follow-up visit or laboratory test)*All cause mortalityProportion of all participants who died6 months (range 5--8) and 12 months (range 9--15)*Verbal autopsy to capture cause of death whenever possible. No death certificate or autopsy report required.*Lost-to-follow-up (LTFU)Proportion of all participants LTFU6 months (range 5--8) and 12 months (range 9--15)*We define participants lost to follow-up if they or their treatment buddies were more than 2 months late for a scheduled consultation or medication pick-up and no information was found about the participant*Transfer out (TO)Proportion of all participants who transferred out to any other health facility (than the initially attached one) with known outcome6 months (range 5--8) and 12 months (range 9--15)*Definition of "known outcome": Documented proof of follow-up visit or laboratory test of the new health facility*Viral suppression \< 1000 copies/mlProportion of all participants with viral suppression (\< 1000 copies/mL)12 months (range: 9--15)*Some of the remote health facilities in the study districts face regular challenges in sending the blood to the government hospital. To ensure sufficient VL measurements among study participants, these health facilities will be equipped with dried-blood-spot (DBS) as a backup for VL measurement. According to the WHO the recommended threshold for treatment failure using DBS is 1000 copies/mL*AdherenceAssessed by 3 different setting- and age-validated ART self-reported adherence questions:1. "When was the last time you missed any medications?" \[i) past week, ii) 1--2 weeks ago, iii) 3--4 weeks ago, iv) never\]: Dichotomous outcome missed doses vs. no missed doses in the past month2. "ART missed at two or more consecutive days within last month?": Dichotomous outcome3. "How would you rate your adherence over the last month" \[i) very poor, ii) poor, iii) fair, iv) good, v) very good, vi) excellent\]: Dichotomous outcome adherent vs non-adherent (anything less than 'excellent')3 months (range 2.5--3.5), 6 months (range 5--8) and 12 months (range 9--15)Quality of lifeAssessed by SF-12 (Likert-Scale)6 months (range 5--8) and 12 months (range 9--15)Satisfaction of careAssessed by a self-reported patient service satisfaction questionnaire partly based on a setting-validated quality of care questionnaire (Likert-Scale)6 months (range 5--8) and 12 months (range 9--15)*Assessed by an external data collector, not the PE*

Data collection and management {#Sec9}
------------------------------

At enrolment, the PE administers a questionnaire integrated in the PEBRApp. Questionnaire domains include sociodemographic and socioeconomic data, medical history, HIV/AIDS knowledge, adherence, quality of life and satisfaction of care. Follow-up data is collected using PEBRApp according to the schedule outlined in Fig. [3](#Fig3){ref-type="fig"}. Baseline VL is defined as the last VL within the previous 12 months. If no VL within previous 12 months available, then the participant is sent to the nurse for routine VL measurement at enrolment. Fig. 3PEBRA trial SPIRIT diagram

The PEBRApp is password-protected and all data is regularly backed up into at a password-protected database. Similarly, relevant data for the SMS intervention is uploaded to a separate encrypted and password-protected online database that offers the possibility to send out SMS automatically and is connected to the district laboratory database containing the VL results. SMS are dispatched using the trusted third-party provider Twilio, certified with the privacy shield framework. Access to all data collection tools and databases are strictly limited and regulated through personal user profiles. The PEBRA trial represents implementation research without any experimental medication and only well-established ART in Lesotho according to the National guidelines. Thus, we do not expect serious adverse effects (SAE) on patients' health from this intervention. However, for the purpose of this trial, we will capture the following SAEs: a) life-threatening event, b) hospitalization, c) persistent or significant disability or incapacity, d) congenital anomaly / birth defect, e) death. It is not planned to establish a data safety and monitoring board.

Sample size and analysis {#Sec10}
------------------------

Based on cohort and program data from the study districts we expect on average 15 AYPLHIV per health facility with an overall viral suppression rate (\< 20 copies/ml) of 70%. An overall target sample size of 300 AYPLHIV in 20 clusters would provide 90% power to detect a 20% increase of viral suppression in the intervention compared to the control group, assuming a type 1 error of 0.05. An intra-cluster correlation coefficient (ICC) of 0.05 (design effect of 1.7) was estimated based on similar studies \[[@CR28], [@CR29]\].

Analyses are performed following the CONSORT guidelines for cluster-randomized trials and an intention-to-treat principle including all participants as randomized per cluster randomization. Clusters are the unit of randomization, but individuals are the unit of analysis. The primary analysis uses random effects logistic regression models including cluster as a random effect and arm allocation as a fixed effect to assess the difference between viral suppression rate in the intervention versus control arm. The model will be further adjusted for the stratification factor, and relevant baseline factors that may be randomly unbalanced between intervention and control clusters. All results are presented with odds ratios and their respective 95% confidence intervals. Categorical variables will be described with absolute and relative frequencies and continuous variables as medians and interquartile ranges. In pre-specified subgroup analyses, the effect of gender, age groups, education, marital status, ART regimen and HIV/AIDS knowledge on key study outcomes will be assessed by including interaction terms in the model. If an interaction term is found to be significant, effect estimates will be summarized by subgroup. As the study is not powered for these pre-planned subgroup analyses, these results will be considered exploratory. Where substantial data are missing in important covariates, multiple imputation will be utilized and the results compared to models ignoring missing data. A sensitivity analysis will be performed to assess the effect of baseline viral load on the primary endpoint, only including participants for whom this data is available. All analyses are done using Stata (version 14, Stata Corporation, Austin, Texas, USA), using two-sided *p*-values and a significance level of 0.05.

Discussion {#Sec11}
==========

Effective and differentiated strategies are needed to improve the HIV care cascade among adolescents and young adults, especially in rural settings in SSA. Although many countries in SSA have some sort of PE program in place, there is lack of published high-quality evidence for adolescent-specific DSD models involving peers \[[@CR20]\].

The Zvandiri DSD model in rural Zimbabwe introduced community adolescent treatment supporters to offer facility-based as well as community-based support for AYPLHIV, including piloting ART delivery through peers. In a small randomized clinical trial the model improved self-reported adherence to ART, engagement in care, and psychosocial well-being \[[@CR24]\]. This effect could no longer be observed at 2 years follow-up in a subsequent larger cluster-randomized trial, however, a 40% reduction in virologic failure was documented among participants in the model \[[@CR25]\]. The questions remain, though, to what extent DSD models can be individualized and peers can be involved in clinical care. In recent years there has been an increasing programmatic shift towards DSD models, however they usually have narrow inclusion criteria and limited options to choose from. The PEBRA model tries to incorporate the existing structures and support options provided by different stakeholders, differentiates the DSD by personal preferences and puts the PE at the heart of the model.

This trial has several limitations. First, as in most operational research studies, we will have only limited control over what happens in our standard care clusters. Second, due to the nature of this pragmatic implementation trial, it is not possible to blind participants or staff to the intervention. Third, it was not feasible to perform the randomization after recruitment of the participants. That means, there is a possibility of recruitment bias. To mitigate this risk, two different consent forms for control versus intervention arm concealing the exact intervention of the other arm were used, thus the participants were aware of being in a study, but not of being in a trial.

The PEBRA trial will provide evidence on the feasibility and effectiveness of an inclusive and holistic DSD model for AYPLHIV that is more preference-based and coordinated by a PE. If proven to be effective, the PEBRA model and PEBRApp have the potential to be scaled up in similar settings.

Trial status {#Sec12}
============

The trial was launched on November 4, 2019. The study is ongoing, and we expect to reach the required minimum target sample size within 5 months. The questionnaires, PEBRApp and the PEBRA model were pretested in a pilot trial from August -- October 2019. The pilot trial assessed the acceptance of the PEBRA model and its delivery by the PE, the technical functionalities of PEBRApp and the questionnaires.
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